Skip to content
StockMarketAgent
Direct answer
Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder. Fair value range: low $176, high $337, with mid-point at $255.
Stock analysis

ISRG Intuitive Surgical Inc. fair value $255–$337

ISRG
By StockMarketAgent.AI team· supervised by
已分析: 2026-05-09下次更新: 2026-08-09Methodology v2.4Archetype: Mature compounderNASDAQ · Health Care
View archive
股价
$450.06
▼ -195.39 (-43.41%)
公允价值
$255
$255–$337
评级
卖出
confidence 87/100
上行空间
-43.4%
upside to fair value
安全边际
$216.47
buy below · 15%
市值
$159.4B
P/E fwd 38.2
英文原文ZH
翻译期间显示英文原文
此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

§1 执行摘要

  • Premium quality compounder with a wide competitive moat.
  • Reverse DCF implies ~20% perpetual growth required at current $450 price.
  • Intrinsic valuation models anchor at $254.67, signaling a massive premium.
  • Sell recommendation driven by extreme valuation disconnect, not business quality.
Fair value
$255
Margin of safety
-76.7%
Confidence
87/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$450.06Price
FV $254.67
High $336.56

Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder.

  • Massive installed base of da
    Massive installed base of da Vinci systems
  • High switching costs for hospitals
    High switching costs for hospitals and surgeons
  • Cycle upside
    Post-pandemic procedure backlog clearance drives elevated system utilization and instrument consumption.

§2 看空情景

A severe hospital capexCapital expendituresCash spent on acquiring or upgrading property, plant, and equipment. Splits into maintenance capex (sustaining current capacity) and growth capex (expanding capacity). freeze combined with accelerated placements of competing systems like Medtronic's Hugo compresses margins and slows new system placements significantly.

该论点可能失败的方式

Medtronic/J&J Capture 30% Market Share

· Low

Competitors successfully disrupt the monopoly, forcing severe pricing pressure on systems and instruments.

FV impact
Downside below $175
Trigger
2-3 Years

Severe Hospital Capex Freeze

· Medium

Macro-driven hospital budget cuts drastically slow new system placements and upgrade cycles globally.

FV impact
Downside to $190
Trigger
1-2 Years

New Modality Disruption

· Low

Emergence of non-robotic, highly effective minimally invasive alternatives permanently reduces TAM for da Vinci.

FV impact
Downside to $160
Trigger
5+ Years
需关注的早期预警信号
指标当前触发阈值
Decline in da Vinci procedure volume growth below 10%MonitorDeterioration versus the report thesis
Compression of gross margins below 60%MonitorDeterioration versus the report thesis
System placement growth turning negative YoYMonitorDeterioration versus the report thesis
Competitor system FDA approvals with superior clinical dataMonitorDeterioration versus the report thesis
Significant insider selling coupled with guidance cutsMonitorDeterioration versus the report thesis

§3 财务历史

损益表 — 最近六期
项目T−0T−1T−2T−3CAGR
期间2022-12-312023-12-312024-12-312025-12-31Trend
营业收入$6.22B$7.12B$8.35B$10.06B+17.4%
毛利$4.20B$4.73B$5.63B$6.64B+16.5%
营业利润$1.58B$1.77B$2.35B$2.95B+23.1%
净利润
每股收益(摊薄)$3.65$5.03$6.42$7.87+29.2%
EBITDA$1.94B$2.22B$2.85B$3.62B+23.1%
研发$879.0M$998.8M$1.15B$1.31B+14.3%
销售管理费用$1.74B$1.96B$2.14B$2.39B+11.1%

质量评分

Piotroski F 评分
7 / 9
0–9 质量综合
Altman Z 评分
39.9
破产风险 (>3 安全)
OCF / 净利润
1.06×
>1 表示盈利质量高
会计质量门槛
Pass
经行业调整门槛
ROIC
13.0%
投入资本回报率
第 3 节

Numbers analysis

个人订阅用户 — §4 及之后还有 11 个章节

阅读完整分析 — 还有 11 个章节。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

涵盖每个股票的完整报告
24 个月的评级存档
关注列表简报 + 评级变更提醒
以任意语言导出 PDF + DOCX
开始免费试用
可随时取消。
FAQ

ISRG — frequently asked questions

  1. Based on our latest analysis, ISRG looks meaningfully overvalued. The current price is $450 versus a composite fair-value midpoint of $255 (range $176–$337), which implies roughly 43.4% downside to the midpoint.
Related coverage

Names readers of ISRG also follow

Same archetype: mature-compounder
Same sector: Health Care